Another study on T1DM subjects showed DC immunotherapy introduced with pancreatic islet cell antigens proved to be safe and well tolerated, induced an immune tolerance response for up to 3 years post-therapy, temporarily decreased CD4+ and CD8+ T cell responses to pancreatic islet cell autoantigens, and increased reg and memory CD4+ T cells after the first injection [57]. The gene discussed is CD4; the disease is type 1 diabetes mellitus.